Search

Cardiovascular diseases are the most common cause of human death in the developing world. Extensive evidence indicates that various toxic environmental factors and unhealthy lifestyle choices contribute to the risk, incidence and severity of cardiovascular diseases. Alterations in the genetic level of myocardium affects normal heart development and initiates pathological processes leading to various types of cardiac diseases. Homeobox genes are a large and highly specialized family of closely related genes that direct the formation of body structure, including cardiac development. Homeobox genes encode homeodomain proteins that function as transcription factors with characteristic structures that allow them to bind to DNA, regulate gene expression and subsequently control the proper physiological function of cells, tissues and organs. Mutations in homeobox genes are rare and usually lethal with evident alterations in cardiac function at or soon after the birth. Our understanding of homeobox gene family expression and function has expanded significantly during the recent years. However, the involvement of homeobox genes in the development of human and animal cardiac tissue requires further investigation. The phenotype of human congenital heart defects unveils only some aspects of human heart development. Therefore, mouse models are often used to gain a better understanding of human heart function, pathology and regeneration. In this review, we have focused on the role of homeobox genes in the development and pathology of human heart as potential tools for the future development of targeted regenerative strategies for various heart malfunctions.

Cardiac muscle is the hardest working muscle in the body, pumping approximately 70 g of blood with every heartbeat, circulating 9500 l of blood daily and contracting over 3 billion times during the average human's life. Heart failure - a heterogeneous syndrome - is a major and increasing health care problem worldwide and a leading cause of hospitalization and morbidity in elderly. Adequate heart tissue regeneration in human is lacking. Challenges to engineer heart tissue and employ it in vitro or in regenerative medicine remain to be solved. First of all, cardiac tissue bioengineering requires robust and powerful cells capable of differentiating into cardiomyogenic lineages in combination with effective, safe and highly specialized biomaterials, hydrogels and/or scaffolds for recreating the native extracellular microenvironment. Advances in stem cell and biomaterial science already provided an increasing array of cell resources, their cultivation technologies and biomatrices for efficient and safe cardiac tissue reconstruction. In order to develop new cardiac tissue mimicking technologies in vitro, it is necessary to analyze the advantages and drawbacks of already established biosystems. Therefore, in this paper, we provide a comprehensive overview of recently employed cells, 2D and 3D biomatrices for cardiac tissue engineering and review the current state-of-the-art in this field as well as future directions.

Abstract: Apoptosis in heart failure has been intensively investigated in vitro and in vivo. Stem cells have therapeutic value in the direct treatment of diseases, including cardiovascular disease. The main drawback of stem cell therapy is their poor survival in the diseased tissues. Since intracellular mitogen-activated protein kinases (MAPKs) actively participate in the regulation of cell survival and of proapoptotic signals, the ability to manipulate the mechanisms of MAPKs activation in myogenic stem cells might increase the survival of transplanted stem cells. Our results clearly demonstrate sustained activation of all three MAPKs, ERK, JNK and p38 in myogenic stem cells after exposure to the NO inducer, NOC-18. Inhibition of MAPKs phosphorylation by specific inhibitors revealed the anti-apoptotic role of MAPKs in myogenic stem cells. [Copyright &y& Elsevier]